Atrial fibrillation and left atrial appendage
T he atrial fibrillation (AF) is the most common cardiac tachyarrhythmia. It affects approx. 1% of general population 1 and this percentage increases with age affecting about 3,8% of patients over 60 years and 9% of patients over 80 years 1 . Stroke is the most debilitating and life-threatening complications of AF. The arrhythmia is associated with even a 5-fold risk of stroke. 2, 3 The frequency of AF in stroke patients admitted to medical departments ranges from 6,5% in younger patients (50-59 year) 2 to over 30% in octogenarians. 2, 4, 5 Thus elderly patients are not only prone to AF, but their stroke risk is also higher. Strokes related to AF are associated with worse prognosis, worse neurological outcome and higher rate of medical complications, including pneumonia, pulmonary oedema and heart failure compared with strokes of other than AF etiology. 4 The probability of remaining disabled or handicapped is increased by almost 50%. 5 The in-hospital and long-term mortality rate are also higher in patients with AF. 4, 5 Blackshear and Odell 6 reviewed twenty three studies that evaluated the presence and location of left atrial thrombus by transoesophageal echocardiography, autopsy or operation. The analysis revealed that left atrial thrombi occur in left atrial appendage in 91% of nonrheumatic atrial fibrillation and in 57% of rheumatic mitral valve disease. Non-rheumatic atrial fibrillation is probably responsible for 15-20% of cerebrovascular accidents of ischaemic origin. 7, 8 The left atrial appendage (LAA) is a remnant of the primary left atrium which forms during third week of embryonic development. 9 The proper left atrial cavity develops later and is formed from the outgrowth of the pulmonary veins.
The LAA has a tubular, hooked and trabeculated structure 9 with considerable heterogeneity among individuals in size, shape, wall thickness and morphology. 10 It is more distensible than the left atrium proper and may augment haemodynamic function as a decompression chamber by modulating left atrial pressure -volu-me relations in states of increased left atrial pressure and volume overload. 9, 11 The LAA also contains stretch receptors that may regulate thirst [11] and other endocrine cells that produce atrial natriuretic peptide 7, 9, 11 and help regulating fluid balance. The cardiocytes of the LAA contain the greatest density of atrial natriuretic peptide granules found in the left atrium. 9, 11 Several authors reported fluid retention after bilateral atrial appendectomy concomitant to maze procedure. [12] [13] [14] In those patients in whom the right atrial appendage was preserved the production of atrial natriuretic peptide was maintained resulting in better diuresis in the postoperative period. [12] [13] [14] The LAA may be also the site of triggers that can induce episodes of AF and of re-entrant drivers that may participate in the AF maintenance. In AF, remodeling as well as impaired blood flow occur in left atrial appendage. 11 These pathological conditions may lead to stasis and thrombus formation. 9 The degree of stasis in LAA is substantially worse than in the right atrial appendage because of differences in the anatomy and blood flow in both appendages. 7
Strategies of pharmacological stroke prevention in atrial fibrillation
According to current guidelines 3 classic OAC and new OAC (NOAC) are recommended to prevent thromboembolic events in atrial fibrillation patients. The CHA 2 D-S 2 VASc score was implemented for stroke risk assessment and to guide treatment choice. Stroke in the past and age over 75 years, based on the CHA 2 DS 2 VASc score, are two factors strong enough to start OAC therapy in patients with AF. The decision to begin therapy must stay in balance with risk of major bleeding, especially intracranial, which is the most serious complication of this therapy with a high risk of disability and death. 3 Therefore HAS-BLED score should be also calculated in each patient to evaluate the risk of bleeding.
There are however even more difficulties associated with OAC, including drug interactions, dietary restriction, poor patient adherence to treatment, labile interna-Srce i krvni sudovi 2014; 33(1): 35-40 tional normalized ratio (INR) and problematic decisions during urgent invasive procedures. 8 The majority of strokes in patients who started OAC occur in subjects who have discontinued OAC or whose INR is subtherapeutic. 15 Moreover, several studies 5, 16 proved that OAC therapy is not properly implemented. Euro Heart Survey Investigators 16 showed that, despite strong recommendations, OAC therapy was properly prescribed only in 60% of high risk patients, whereas 28% were undertreated and 11% overtreated. Similar results were presented in systematic review of 54 studies performed by Ogilvie et al. 17 with treatment level ranging from 39% to 92,3% of high risk patients based on the CHADS2 risk score. High discontinuation rate (30%) was also underlined 17 . Moreover, there are several contraindication for OAC, including evidence of active bleeding, history or predisposition to intracranial bleeding, uncontrolled severe hypertension, recent brain, eye or spinal cord surgery or injury, propensity for recurrent falling, inability for INR monitoring, and patient non-compliance.
The NOAC have shown non-inferiority compared with classical OAC and better safety limiting the number of intracranial hemorrhage 18, 19 . Nevertheless, many problems with oral anticoagulation remained unresolved. Dabigatran and rivaroxaban are contraindicated in severe kidney disease (with creatinine clearance lower than 30 mL/min), and the dose should be reduced in the presence of high bleeding risk (HAS-BLED score ≥3), moderate kidney disease (with creatinine clearance 30-49 mL/min), as well as in elderly patients (≥80 years) and if concomitant use of interacting drug (werapamil) is necessary for dabigatran. The risk of major bleeding is similar among NOAC and estimated as 3,36-3,6% per year during rivaroxaban therapy 18, 19 , 3,4% per year during warfarin therapy 19 and 2,71% per year during treatment with dabigatran 110mg daily and 3,11% per day with the daily dose 150mg of dabigatran 18 . ROCKET-AF study 19 revealed that rates of intracranial hemorrhage were significantly lower in the rivaroxaban group than in the warfarin group (0,5% vs. 0,7% per year). However major bleeding from a gastrointestinal site was more common in the rivaroxaban group (3,2%), as compared with warfarin group (2,2%).
Left atrial appendage closure as alternative to pharmacological therapy
Though there are several pharmacological antithrombotic possibilities, some groups of patients with several contraindications, especially high risk of bleeding and with history of bleeding complications, cannot be offered any of them. Therefore, LAA closure may be an attractive alternative. Attempts to decrease risk of LAA thrombus embolisms resulted in development of surgical excision and percutaneous LAA occlusion techniques. James Cox 7 , on the basis of surgical studies and his own observations, concludes that removal or proper closure of the LAA at surgery reduces the risk of perioperative and long-term stroke. According to current guidelines 3 LAA surgical excision may be considered in patients undergoing open heart surgery (IIb C). Inter-ventional percutaneous LAA closure may be considered in patients with a high stroke risk and contraindications for long-term oral anticoagulation. The LAA closure devices are designed to seal the neck of LAA and reduce thrombus embolization 20 .
Currently, two LAA closure devices are available for clinical use -Watchman TM left atrial appendage closure device (Watchman device) (Boston Scientific) and Amplatzer TM Cardiac Plug (Amplatzer device) (St. Jude Medical).
The Watchman device was introduced in 2005. It was designed to be permanently implanted at or slightly distal to the ostium of LAA to trap thrombus before it exits the LAA. The Watchman LAA Closure Technology consists of the Watchman transseptal access system, delivery catheter and an implantable device. The Watchman device is a self-expanding nitinol frame (Fig-1a and Fig-1b ). It is available in 5 sizes (21-33mm) and is preloaded within a delivery catheter.
Several studies have shown the feasibility of percutaneous LAA occlusion [20] [21] [22] [23] [24] [25] . The first randomized study, the Percutaneous Closure of the Left Atrial Appendage versus Warfarin Therapy for Prevention of Stroke in Patients with Atrial Fibrillation (PROTECT-AF) trail 22 , evaluated the efficacy and safety of the Watchman device compared with standard warfarin therapy. The trial revealed that the efficacy of percutaneous closure of the LAA with the Watchman device is non-inferior to ongoing warfarin therapy with regard to prevention of stroke, systemic embolism, and cardiovascular death. Moreover, the newest analysis of 5 year follow-up of the PROTECT-AF trial revealed significant reduction in cardiovascular (60%) and all-cause mortality (34%) in patients treated with the Watchman device compared with warfarin group 26 .
The data from the PROTECT-AF study were confirmed by CAP Registry 27 and PREVAIL study 28 which also showed decreased procedure time, improved implant success and procedure/device related safety with increased operator experience. It must be pointed out that these 3 studies were performed in patients who were eligible to take warfarin.
The ASAP study 29 evaluated the safety and feasibility of the Watchman device for the treatment of non-valvular atrial fibrillation in patients with a contraindication to warfarin. The study showed that Watchman implantation for warfarin contraindicated AF patients is feasible, associated with low, but manageable, rate of device thrombus and decreases the rate of stroke by 77%.
The U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee voted on Dec. 11, 2013 favourably by a majority (13 to 1) that the benefits of the WATCH-MAN Left Atrial Appendage Closure device outweigh the risks, there is a reasonable assurance that the device is safe and of a reasonable assurance of efficacy. The final decision and approval from the FDA is expected in the first half of 2014 and this innovative technology will be available to patients with AF at higher risk for stroke who need an alternative to long-term warfarin therapy also in USA.
The data regarding the clinical usage of the Amplatzer Cardiac Plug are based on reports of single-centre experience and registries 23, 25 . Up to now there are no randomized trials comparing Amplatzer device with oral anticoagulants, thus, in authors opinion, their usage should be for now limited to clinical trials.
Left atrial appendage closure procedure with the Watchman device
The procedures may be done under general (preferably) or local anesthesia and with the use of transoesophageal echocardiography and fluoroscopy in a catheterization laboratory ( Fig. 2a-2b; Fig 3a-3d) . Vascular access is obtained with puncture of femoral vein. After cannulation of the femoral vein, a mid-low and posterior transseptal puncture is performed under transoesophageal echocardiography guidance using conventional transeptal needle and delivery sheat. Heparin is then given to keep an ACT above 250 sec. Then, the Watchman Access Sheath and Dilator are advanced over a guidewire into the left atrium. The LAA is engaged with a 5F-6F pigtail catheter to perform selective angiograms. The Access Sheath is then carefully advanced into the distal portion of the LAA over a pigtail catheter. The LAA morphology is then carefully analysed in both angiograms and transoesophageal echocardio-graphy to determine which size of the Watchman device should be implanted. Precise measurements of LAA are carried out in transoesophageal echocardiography in 0, 45, 90 and 135 degree. The Watchman Delivery System is prepared, inserted into the Access Sheath, and slowly advanced under fluoroscopic guidance. The Watchman Device is then deployed into the LAA. The device release criteria are confirmed via fluoroscopy and TEE prior to releasing the device.
Periprocedural complications are the major problem of interventional LAA closure, especially during learning phase. The overall complication rate could be as high as 8,7-11,7%. 20, 22, 27, 29 Most often are pericardial effusion (1,1-5,0%), cardiac tamponade (1,1-1,3%), major blee- Figure 3d . The Watchman device immediately after release from delivery cable ding (3,5%), puncture site complications (2%), thrombus formation on the device (0,7-1,1%) or on the sheath (0,6%), device embolization (0,6-1,7%), air embolization (1,7%), ischemic stroke (0,7-1,1%) or hemorrhagic stroke (0,2%) or TIA (0,6%). 20, 22, 27, 29 In PROTECT-AF trial 22 twenty one of 463 subjects assigned to the intervention group died during the study, however no deaths were deemed related to the Watchman device. Similarly no deaths device or procedure related were reported in the ASAP study 29 and in Matsuo el al. study 20 . According to results of CAP and PREVAIL 27, 28 there is a significant improvement in the safety of Watchman left atrial appendage closure with increased operator experience. In the study performed by Reddy et al. 27 the cohort included 542 patients of the PROTECT-AF trial and a subsequent registry of 460 patients undergoing Watchman implantation (Continued Access Protocol -CAP Registry). A remarkable reduction in the rate of procedure-or device-related safety events was observed, including reduction in procedural time (mean 62±34minutes in PROTECT-AF and mean 50±21minutes in CAP), the rate of serious pericardial effusion (5% in PROTECT-AF to 2,2% in CAP), device embolization (3 cases in PRO-TECT-AF and none in CAP), and periprocedural stroke rates (0,9% in PROTECT-AF and no strokes in CAP). The successfulness of implantation increased from 89,5% in PROTECT-AF to 95% in CAP. Pericardial effusion was the major component of early safety events in PROTECT-AF. Based on the review of procedural details, fluoroscopy and TEE imaging, a variety of causes of pericardial effusion were recognized, ranging from being the result of transseptal puncture, the delivery sheath, or the actual manipulation of the Watchman device itself. The rate of serious pericardial effusion in CAP was less than half that seen in PROTECT-AF. There was also experience-related improvement in periprocedural stroke rate. This complication was largely related to the inadvertent introduction of air entrapped within the sheath to the systemic circulation during the procedure. With careful sheath management, there have been no periprocedural strokes in the CAP registry. Similarly, procedural protocol changes implemented over the study period, resulted in decrease in device embolization rate. Importantly, the safety events rates in the Watchman group had a skewed distribution with a large initial event rate, and subsequent rate during follow-up, while the safety events in the warfarin group occurred at approximately constant rates over time and would be expected to continue to accumulate linearly potentially beyond the end of the study period 27 . Not surprisingly, in Reddy et al. 24 analysis the exclusion of periprocedural adverse events favored the device strategy. After exclusion of events that occurred on the day of device deployment, fewer patients experienced the primary efficacy events in device than in the control warfarin group (postprocedure, 2,5% per year versus 4,3% per year). The similar result was found when analysis was confined to patients who stopped warfarin after successful device deployment (2,3% per year versus 4,1% per year), as well as those who completed therapy with warfarin and clopidogrel and were only taking aspirin (2,3% per year versus 4,1% per year in control group). These analyses suggest that after successful procedure, the LAA device is more effective than continued warfarin therapy.
Post-interventional anti-thrombotic treatment schedule is not clearly established yet. PROTECT-AF [22] patients were treated with warfarin for 45 days to facilitate device endothelialisation. Warfarin was then stopped depending on the result of the transoesophageal echocardiography 45 days after the procedure (lack of flow around the device) and pharmacotherapy was continued with clopidogrel 75 mg daily for 6 months and aspirin (81-325 mg daily) for long term use. The non-randomised ASAP study29] showed that treatment with aspirin and clopidogrel in patients with contraindications for even short term anticoagulation is feasible, safe and effective.
